- Home
- CDTG vs CELU Comparison
CDTG vs CELU Comparison
Compare CDTG & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTG
- CELU
- Stock Information
- Founded
- CDTG 2012
- CELU 2016
- Country
- CDTG China
- CELU United States
- Employees
- CDTG N/A
- CELU N/A
- Industry
- CDTG
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- CDTG
- CELU Health Care
- Exchange
- CDTG NYSE
- CELU Nasdaq
- Market Cap
- CDTG 36.4M
- CELU 40.9M
- IPO Year
- CDTG 2024
- CELU N/A
- Fundamental
- Price
- CDTG $3.07
- CELU $2.46
- Analyst Decision
- CDTG
- CELU
- Analyst Count
- CDTG 0
- CELU 0
- Target Price
- CDTG N/A
- CELU N/A
- AVG Volume (30 Days)
- CDTG 48.0K
- CELU 3.1M
- Earning Date
- CDTG 11-26-2024
- CELU 11-07-2024
- Dividend Yield
- CDTG N/A
- CELU N/A
- EPS Growth
- CDTG 28.29
- CELU N/A
- EPS
- CDTG 0.81
- CELU N/A
- Revenue
- CDTG $34,209,919.00
- CELU $42,690,000.00
- Revenue This Year
- CDTG N/A
- CELU N/A
- Revenue Next Year
- CDTG N/A
- CELU $233.89
- P/E Ratio
- CDTG $3.81
- CELU N/A
- Revenue Growth
- CDTG 18.58
- CELU 182.02
- 52 Week Low
- CDTG $2.12
- CELU $1.30
- 52 Week High
- CDTG $4.60
- CELU $7.97
- Technical
- Relative Strength Index (RSI)
- CDTG N/A
- CELU 49.49
- Support Level
- CDTG N/A
- CELU $3.26
- Resistance Level
- CDTG N/A
- CELU $4.34
- Average True Range (ATR)
- CDTG 0.00
- CELU 0.84
- MACD
- CDTG 0.00
- CELU 0.11
- Stochastic Oscillator
- CDTG 0.00
- CELU 29.59
About CDTG CDT ENVIRONMENTAL TECH INV HLDG LTD
CDT Environmental Technology Investment Holdings Ltd is a waste treatment company. The company generates revenue through the design, development, manufacture, sales, installation, operation and maintenance of sewage treatment systems and by providing sewage treatment services. It engages in two business lines namely, rural sewage treatment and septic tank treatment in both urban and rural areas.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.